Thomas Brinkman

Director, Regulatory Clinical Science at ImmunityBio, Inc.

Role: Director, Regulatory Clinical Science at ImmunityBio, Inc.
Location: Brooklyn, NY, US
LinkedIn followers: 500 followers

OtherView LinkedIn profile

About Thomas Brinkman

Experienced Clinical Scientist with a demonstrated history of working in the clinical research & health care industry.

Experience

Director, Regulatory Clinical Science
ImmunityBio, Inc.
Sep 2024 — Present

Education

New York University
Master of Science - MS, Clinical Research
2019 — 2021
Rutgers University
Bachelor of Science (B.S.), Biotechnology
2012 — 2016

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@immunitybio.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

ImmunityBio, Inc.

Biotechnology Research · 661 employees · Founded 2014 · San Diego, California, United States

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory. Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. "At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman

immunitybio.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About Thomas Brinkman

Experience

Director, Regulatory Clinical Science

Education

New York University

Rutgers University

Find verified contacts for anyone on LinkedIn